Oct 11, 2026
Persistent erectile dysfunction can identify an opportunity to assess vascular risk earlier. The mechanisms are plausible and the association is clinically relevant, but neither establishes a coronary diagnosis.
Persistent erectile dysfunction deserves a cardiovascular assessment, particularly when it develops gradually without an obvious explanation. The useful question is whether the same vascular pathology is affecting erectile function and increasing cardiovascular risk. Answering that takes more than a testosterone measurement or a prescription for tadalafil.[6][7]
A 2026 perspective in Medicina revisits this connection, bringing together vascular physiology, observational studies, and recommendations from the Princeton IV Consensus. There are no new patients, no randomized intervention, and no systematic meta-analysis in that paper. Its value is in connecting existing evidence. Each component still needs to be judged on what it actually establishes.[1]
An erection requires relaxation of both penile arterial smooth muscle and the trabecular smooth muscle within the corpora cavernosa. Nitrergic nerves and endothelial cells supply nitric oxide (NO). That activates soluble guanylate cyclase, increases cyclic guanosine monophosphate (cGMP), and activates protein kinase G. Downstream changes reduce intracellular calcium and contractile activity, allowing the tissue to relax.[2][3]
Arterial inflow increases, the cavernosal sinusoids expand, and that expansion compresses the subtunical venous channels against the tunica albuginea. Restricting outflow is essential to rigidity. A man can therefore have erectile dysfunction from impaired arterial inflow, defective relaxation, or structural changes that prevent effective veno-occlusion. Describing all of those as a blocked artery would be inaccurate.[1]
The nitric oxide mechanism has experimental support. In a classic human tissue study, Rajfer and colleagues electrically stimulated cavernosal strips obtained during penile prosthesis surgery. Inhibiting nitric oxide synthesis reduced relaxation. Providing excess L-arginine largely reversed that inhibition, and inhibiting cGMP breakdown enhanced relaxation. Those experiments support a specific signaling pathway. They don't tell us whether a particular man has coronary atherosclerosis.[3]
Diabetes illustrates how that pathway can fail. Hyperglycemia, oxidative stress, endothelial dysfunction, and autonomic neuropathy can coexist. In a small human tissue study, investigators compared 9 men with type 2 diabetes and severe erectile dysfunction with 6 controls. Diabetic tissue showed greater nitric oxide synthase uncoupling and increased markers of oxidative stress. The controls were undergoing surgery for penile cancer, so this was a selected tissue comparison with substantial limitations. It supports biological plausibility; it cannot quantify cardiovascular risk or establish a treatment benefit.[4]
Clinically, the important point is that vascular function can deteriorate before a large artery becomes critically narrowed. Erectile tissue depends on a rapid, coordinated change in vascular resistance. That makes impaired vasodilation relevant even when there is no obvious flow-limiting coronary lesion.[1][2]
The artery-size hypothesis offers one explanation for earlier erectile symptoms. Penile arteries are roughly 1–2 mm in diameter, compared with approximately 3–4 mm for major coronary arteries. A similar burden of vascular disease may become functionally important earlier in the smaller circulation.[1]
That is plausible, but the vessels are not identical pipes that accumulate plaque at an identical rate. Endothelial function, smooth-muscle behavior, autonomic tone, and local anatomy also matter. The artery-size hypothesis does not let us infer a coronary stenosis from an erectile symptom.[1]
The often-quoted 2–5-year interval between erectile dysfunction and clinical coronary disease needs the same care. It summarizes patterns observed across particular populations. Some studies began with men who already had coronary disease and asked when erectile symptoms started. That introduces selection and recall issues. It gives us a reason to assess risk earlier, rather than an individual countdown to a heart attack.[1]
Prospective evidence is more useful for estimating what happens next. In the Multi-Ethnic Study of Atherosclerosis (MESA), 1,757 men without a prior cardiovascular event were followed for about 3.8 years after an erectile-function assessment. Cardiovascular events occurred in 6.3% of those reporting erectile dysfunction and 2.6% of those without it. That is an observed absolute difference of 3.7 percentage points.[5]
After adjustment for measured risk factors, depression, and beta-blocker use, the hazard ratio was 1.9, with a 95% confidence interval of 1.1–3.4. There was a meaningful association, with appreciable uncertainty around its size. Those absolute rates came from an older cohort and should not be transferred directly to a healthy 35-year-old.[5]
The assessment used a single question and couldn't distinguish vascular from nonvascular erectile dysfunction. Adjustment also cannot eliminate unmeasured confounding. The study supports taking the symptom seriously as a risk marker. It doesn't show that erectile dysfunction itself caused the events, or that treating the erection would prevent them.[5]
The erectile problem and cardiovascular risk need to be assessed in parallel.
Ask about onset, progression, consistency, and the difference between partnered sex, masturbation, and spontaneous morning erections. Ask about desire separately from erectile rigidity. Review depression, anxiety, sleep, alcohol, and medication changes. A sudden, situational problem with preserved spontaneous erections suggests a different balance of contributors from a progressive loss across settings. Neither pattern is perfectly diagnostic, and vascular and psychological contributors commonly coexist.[7][9]
The examination and initial investigations should address actual decisions. Measure blood pressure properly. Review smoking, diabetes, kidney disease, abdominal adiposity, and family history of premature cardiovascular disease. Obtain a lipid profile and glucose or hemoglobin A1c when indicated. Use those findings to estimate absolute cardiovascular risk and identify conditions that already warrant treatment.[6][7]
Morning total testosterone belongs in the erectile-dysfunction evaluation. If it's low, confirm it on a separate appropriately timed sample and interpret it with symptoms and the clinical context. Low desire increases the relevance of hypogonadism, but erectile dysfunction alone doesn't establish the diagnosis. A testosterone prescription doesn't remove the need to evaluate blood pressure, lipids, or diabetes.[7][8]
Medication review also requires judgment. Antidepressants, some antihypertensives, and opioids can contribute. The condition being treated may itself impair sexual function. Establish the timing and discuss alternatives rather than telling someone to stop necessary treatment. Similarly, snoring, witnessed apneas, or daytime sleepiness should prompt assessment for sleep apnea when appropriate.[1][7]
Penile duplex ultrasound is a second-level investigation when defining the vascular mechanism would help management. After pharmacologic stimulation, systolic flow helps assess arterial inflow, while persistent diastolic flow can suggest inadequate veno-occlusion. Interpretation depends on achieving adequate smooth-muscle relaxation. Anxiety or an insufficient drug response can produce misleading results, including a false impression of vascular dysfunction. So an abnormal measurement needs context. The test characterizes penile hemodynamics; it doesn't replace coronary risk assessment, and most men don't need it as their first investigation.[9]
Princeton IV recommends using erectile dysfunction to inform cardiovascular risk assessment and supports calcium scoring to refine risk, particularly when estimated risk is borderline or intermediate. That can be useful when the result would change preventive treatment. It doesn't establish that every man with erectile dysfunction benefits from a scan.[6][12]
A calcium score measures calcified coronary plaque. It doesn't directly measure penile endothelial function, and a score of zero doesn't exclude noncalcified plaque. The question before ordering it is what decision the result will change. A symptomatic man with exertional chest pressure needs evaluation of that symptom, rather than reassurance from a screening pathway designed for someone without symptoms.[10][11]
Treatment of erectile dysfunction can proceed alongside appropriate prevention. Sildenafil and tadalafil inhibit phosphodiesterase type 5 (PDE5), slowing cGMP breakdown. They amplify the erectile signaling response; they do not demonstrate that the upstream vascular problem has disappeared. A good response to tadalafil cannot be used as evidence that cardiovascular risk is low.[2][9]
Observational reports of fewer cardiovascular events among men taking these drugs are interesting. Prescribing decisions, baseline health, and the ability to remain sexually active can differ between users and nonusers. Those differences complicate causal interpretation. Such findings don't establish an indication to prescribe tadalafil solely for prevention of myocardial infarction.[12]
PDE5 inhibitors must not be combined with nitrate medications or recreational nitrites because blood pressure can fall dangerously. Anyone developing chest pain after taking an erectile-dysfunction drug needs urgent assessment and must tell the treating team exactly what they took and when.[9]
For cardiovascular prevention, act on the risks you actually find. Treat hypertension, diabetes, and atherogenic lipid exposure according to the person's risk. Address smoking, inactivity, excess adiposity, and sleep problems. Erectile function may improve with risk-factor modification, but improvement isn't a validated substitute for measuring blood pressure, glycemic control, or cardiovascular outcomes.[6][9]
Showing that erectile dysfunction predicts events is one question. Showing that adding a particular screening program for men with erectile dysfunction reduces heart attacks or mortality is another. The 2026 perspective doesn't answer that second question. Expert recommendations combine the association, biological plausibility, and established benefits of treating cardiovascular risk factors.[1][6]
For new, persistent, or worsening erectile dysfunction, arrange a clinical evaluation rather than assuming age, stress, or testosterone explains it. Chest pressure, severe breathlessness, fainting, or sudden neurologic symptoms require urgent care.[7][11]
A change in erectile function can reveal an opportunity to identify vascular risk earlier. Take a proper history, assess the mechanisms, measure the relevant risks, and treat what the evidence supports. That is the clinical value of the signal.
This article is educational and is not an individual diagnosis or treatment plan.
